Cytek Biosciences, Inc. reported $207M of revenue over the trailing twelve months, +5.4% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $207M (to Q2 2026). Net income: −$81M, trailing twelve months to Q2 2026. Free cash flow: −$12M, trailing twelve months to Q2 2026. Operating margin: −23%, trailing twelve months to Q2 2026.

CTKBCytek Biosciences, Inc.

Healthcare

$5.59+36% 1Y

$5.59

$3.3652 weeks$6.09

CTKB as reported

Cytek Biosciences, Inc. reported $207M of revenue over the trailing twelve months, +5.4% on the year before. 10 reported series are charted on this page, each one as filed.

$207M

Revenue, trailing twelve months · to Q2 2026 · +5.4% against the twelve months before

Net income: −$81M
Net income · +1159% year on year · trailing twelve months to Q2 2026
Free cash flow: −$12M
Free cash flow · −211% year on year · trailing twelve months to Q2 2026
Operating margin: −23%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CTKB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$207M	+5.4%	Q2 2026
Net income	−$81M	+1159%	Q2 2026
EPS	−$0.62	+1140%	Q2 2026
Gross margin	53%	n/a	Q2 2026
Operating margin	−23%	n/a	Q2 2026
Net margin	−37%	n/a	Q2 2026
ROE	−18%	n/a	Q2 2026
ROA	−13%	n/a	Q2 2026
ROIC	−43%	n/a	Q2 2026
Free cash flow	−$12M	−211%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.